SEATTLE--(BUSINESS WIRE)--Jun. 7, 2022--
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the appointment of industry veteran Andrew S. Sandler, M.D., as its Chief Medical Officer. Dr. Sandler joins Alpine from Kiadis Pharma, a Sanofi Company, where he was Chief Medical Officer. Dr. Sandler’s anticipated start date is August 17, 2022.
“We are very excited and fortunate to have Andy join the Alpine team. His appointment comes at a time where we are quickly advancing our three development programs across multiple oncology and autoimmune disease indications,” said Stanford Peng, M.D., Ph.D., President and Head of Research and Development at Alpine. “Andy is a highly experienced Chief Medical Officer with extensive clinical development expertise, and has a passion for developing novel therapies for patients with life-threatening and debilitating diseases.”
“I am thrilled to join the Alpine team and continue to advance the clinical strategy and development of the company’s extremely promising pipeline, including acazicolcept, davoceticept, and ALPN-303,” said Dr. Sandler. “I look forward to integrating with the development teams to continue to advance these exciting therapies that were built from Alpine’s directed evolution platform and have the potential to improve the lives of many patients.”
Dr. Sandler brings over 25 years of industry and clinical practice experience. Prior to his role at Kiadis Pharma/Sanofi, Dr. Sandler was Senior Vice President of Medical Affairs at Medivation (Pfizer). Before that, Dr. Sandler held various roles including Chief Medical Officer, Executive Vice President, Research and Development, Seattle Site Head, and Senior Vice President, Clinical and Medical Affairs at Dendreon Pharmaceuticals. Earlier in his career, Dr. Sandler was Chief Medical Officer at Spectrum Pharmaceuticals and Vice President and Head of Global Medical Affairs for Oncology at Bayer Healthcare Pharmaceuticals. Dr. Sandler also previously held various positions at Berlex Oncology/Schering AG and Seattle Genetics, Inc.
Dr. Sandler holds a B.S. degree in Neuroscience from the University of Rochester. He obtained his M.D. degree and completed his residency in Internal Medicine at Mount Sinai Medical Center, followed by a fellowship in Hematology/Oncology at the University of California, San Francisco. Dr. Sandler also holds a Certificate in Epidemiology and Biostatistics.
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on Twitter and LinkedIn.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding our platform technology and potential therapies; the potential efficacy, safety profile, future development plans, addressable market, regulatory success, and commercial potential of our product candidates; and our ability to successfully develop and achieve milestones in our development programs. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “intend,” and other similar expressions, among others. These forward-looking statements are based on current assumptions that involve risks, uncertainties, and other factors that may cause actual results, events, or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: clinical trials may not demonstrate safety and efficacy of any of our product candidates; our ongoing discovery and preclinical efforts may not yield additional product candidates; our discovery-stage and preclinical programs may not advance into the clinic or result in approved products; any of our product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones in our proprietary or partnered programs; the impact of competition; adverse conditions in the general domestic and global economic markets; the impact of the COVID-19 pandemic on our business, research and clinical development plans and timelines and results of operations, including the impact on our clinical trial sites, collaborators, and contractors who act for or on our behalf, may be more severe and prolonged than currently anticipated; as well as the other risks identified in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and we undertake no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220607005406/en/
Director, Investor Relations and Corporate Development
Alpine Immune Sciences, Inc.
Source: Alpine Immune Sciences, Inc.